- $332.00m
- $220.26m
- $56.20m
908 Devices Inc. expected to post a loss of 36 cents a share - Earnings Preview
908 Devices Inc. reports results for the quarter ended in December - Earnings Summary
Brief: 908 Devices Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: 908 Devices sees FY 2023 revenue USD 48-52 million
908 Devices Inc. expected to post a loss of 26 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Calithera Biosciences, Haynes International, Lumos Pharma
908 Devices down on downbeat 2022 sales forecast
908 Devices Inc. reports results for the quarter ended in September - Earnings Summary
Brief: 908 Devices Reports Third Quarter 2022 Financial Results
908 Devices Inc. expected to post a loss of 22 cents a share - Earnings Preview
908 Devices Inc. reports results for the quarter ended in June - Earnings Summary
Brief: 908 Devices Reports Q2 Loss Of 26 Cents Per Share
Brief: 908 Devices Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: 908 Devices Reports First Quarter 2022 Financial Results, Reiterates 2022 Revenue Outlook
908 Devices Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: 908 Devices And CPI Team On Cell Culture Media Optimization For Improved Process Control In Bioprocessing Applications
U.S. RESEARCH ROUNDUP- Cara Therapeutics, DT Midstream, Fulcrum Therapeutics
908 Devices Inc. reports results for the quarter ended in December - Earnings Summary
Brief: 908 Devices Reports Q4 And Full Year 2021 Financial Results